• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

DeepIntent Receives Patent for Technology that Enables Marketers to Reach Precise Patient Populations in a HIPAA-Compliant, Privacy-Safe Manner


DeepIntent announced that the United States Patent and Trademark Office has granted the company a patent for its Patient Modeled Audiences technology that enables pharmaceutical advertisers to reach highly-qualified patient audiences with speed and precision, in a privacy-safe way.

Advertisers can use comprehensive real-world clinical datasets to increase audience quality and improve programmatic campaign performance. The patent positions DeepIntent as the only demand side platform (DSP) that can use the HIPAA-compliant Patient Modeled Audiences technology to determine the correlation between demographics and disease to create precise, campaign-specific modeled audiences.

“Healthcare marketers seeking to raise awareness of new clinical trials and treatments among patients, especially those suffering from rare diseases, have had to cast a wide net to reach clinically-relevant audiences because they didn’t have a solution that offered the necessary scale and precision in a privacy-safe way. The inefficiencies of many existing solutions has led to wasted ad dollars and missed opportunities to improve patient health,” said DeepIntent Founder and CEO Chris Paquette. “Patient Modeled Audiences is a game-changing technology that unlocks the value of real-world healthcare data to improve the audience quality of programmatic campaigns. It represents a huge step forward in our mission to use data science to help marketers reach patients with information that can improve their quality of life.”

DeepIntent’s patented technology is equally as successful at reaching qualified patient audiences for common conditions such as Chronic Obstructive Pulmonary Disease (COPD) and Plaque Psoriasis as it is for low-incidence and rare conditions with a fraction of the prevalence, such as Multiple Sclerosis and Hereditary Angioedema (HAE). The unique technology empowers marketers to reach rare disease patients during the narrow, critical window soon after diagnosis, increasing the likelihood of getting patients on therapy and on their way to wellness.

Related Videos